Kingbury: pricey but smart
Article Abstract:
Kingbury is a UK furniture retailer which has seen a rise in its share price. The company aims to increase the number of its stores to 100 from 75. Out of town stores account for 54 of Kingsbury's existing stores. The expansion is to be funded from cash flow, with new stores bought as leaseholds. The company faces intense competition in this market, but does not offer interest-free credit so should avoid a reaction from consumers if the real cost of such deals becomes apparent. The company's profit is forecast at 6 million pounds sterling by Credit Lyonnais Laing.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Bucking the high street trend
Article Abstract:
Heal's has performed well for a United Kingdom retailer, and the company's upmarket position has given it some protection from the difficult conditions affecting retailers. The company has had problems in locating appropriate sites and will open a new store in Kingston-upon-Thames. Heal's also aims to open stores in Glasgow and Manchester in the UK, and Dublin, Ireland. The company's profit is not forecast to rise a great deal in 1998 but its growth rate should increase in 2000.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Heal's
Article Abstract:
Heal's has potential for expansion and its four stores are performing better than expected, while its brand name is strong. The company has problems locating appropriate sites at a reasonable rent.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Picking the right time. Wall Street's ahead. The stuff of dreams
- Abstracts: Finsbury Worldwide Pharma Trust. Herald Investment Trust. Prelude Trust
- Abstracts: New inroads to US markets. Exchange fudges on costs. Bridging the gap
- Abstracts: Pulling green biotechnology out of the red. Drug screening-beyond the bottleneck. Experts disagree over color of biomass
- Abstracts: Semiconductors' stunning ride beckons buying on weakness. Hewlett Packard. Dell buoyed